X

Trial Profile

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Escitalopram (Primary)
Indications Anxiety
Focus Therapeutic Use
Acronyms FiESTAA

Most Recent Events

04 Nov 2020 Status changed from recruiting to completed.
25 Aug 2020 Primary endpoint (change in PARS score from baseline to week 8 and change from baseline in CGI-S and CGI-Improvement scale (CGI-I) response (defined as a CGI-I score of 1 or 2)) has been met, as per results published in the Journal of Clinical Psychiatry
25 Aug 2020 Results published in the Journal of Clinical Psychiatry

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com